Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~1. Histopathologically or cytologically confirmed, advanced or metastatic breast cancer (stage IIIb, IIIc or IV disease) including inflammatory breast cancer or inoperable locally advanced disease.~2. Documented ErbB2 overexpression~3. Estrogen receptor positive (ER+) and/or progesterone positive (PgR+) tumors~4. Measurable or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria~5. A life expectancy of \> 3 months for Phase 1 and \> 6 months for Phase 2~6. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 at study entry in Phase 1 and ≤ 1 in Phase 2;~7. Normal cardiac ejection fraction~8. Adequate hematologic, hepatic and renal function~9. Post-menopausal female (defined as the absence of a menstrual cycle for at least 12 consecutive months) or male subjects ≥ 18 years of age.~10. Sign an IRB or EC approved informed consent~Exclusion Criteria~1. Type 1 diabetes or uncontrolled Type 2 diabetes~2. Subjects showing clinical evidence or with a history of cataract(s), proliferate retinopathy or significant macular edema~3. Subjects with abnormal free T4 values and a history or evidence of thyroid disease~4. Subjects who are unable or unwilling to take metformin~5. Uncontrolled intercurrent illness~6. Known or suspected human immunodeficiency virus (HIV) infection or hepatitis B or C~7. Subjects with inflammatory diseases of the gastrointestinal tract~8. History of other malignancy. Subjects who have been disease free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;~9. Subjects with extensive symptomatic visceral disease including hepatic involvement and pulmonary lymphangitic spread of tumor~10. A history of prior treatment with other agents specifically targeting IGFRs~11. Subjects who require pharmacological doses of glucocorticoids beyond replacement doses. The use of topical, intra-ocular or inhalation glucocorticoids is permitted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escallation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).